-
Tactogen is a
public benefit corporation and start-up
pharmaceutical company based in Palo Alto,
California that is
developing novel MDMA-like entactogens...
- in the
psychedelic medicine movement.
Baggott is co-founder and CEO of
Tactogen, a
public benefit corporation started in 2020 that is
developing novel...
- = 7,252 nM). TACT908 is
under development by
Tactogen. It was
patented by
Matthew Baggott and
Tactogen in 2023. As of
January 2025, the drug is in preclinical...
-
similar to MDMA in its
structure and effects. It has been
patented by
Tactogen as an
entactogen for
potential use as a medicine. 5-MAPB acts as a...
-
system replaced by benzofuran. The drug was
patented by
Matthew Baggott and
Tactogen in 2022. 6-APB 5-MAPB WO 2022/032147,
Baggott M, "2-Aminoindane compounds...
- methylone. It was
patented by
Matthew Baggott and
Tactogen and is
under investigation by
Tactogen for
potential medical use. It acts as a
monoamine releaser...
- disorder, anorexia, and binge-eating disorder. It is
being developed by
Tactogen. As of the
first quarter of 2025, the drug is in the
preclinical research...
-
analogue of
dimethyltryptamine (DMT)). 1ZP2MA and 2ZEDMA were
patented by
Tactogen in 2023. 1Z2MAP1O α-Methylisotryptamine (isoAMT) BK-NM-AMT 3-APBT WO patent...
-
transporter (SERT) was not reported. 1Z2MAP1O was
patented by
Matthew Baggott of
Tactogen in 2023. 2ZEDMA 1ZP2MA α-Methylisotryptamine (isoAMT) TACT411 TACT833 WO...
- BK-NM-AMT and its 5-halogenated
analogues were
patented by
Matthew Baggott and
Tactogen in late 2024. α,N-Dimethyltryptamine (NM-AMT) 1Z2MAP1O 1ZP2MA Serotonin–dopamine...
